Liraglutide and migraine: why the small pilot is not a treatment promise

The interesting result has an important missing comparison

The 2025 liraglutide migraine pilot reported a substantial fall in headache days. The catch is that everyone in the study received liraglutide: there was no placebo group and no masking. That makes the result worth investigating while leaving the drug’s contribution uncertain. I would read the headline as a question about future migraine research, rather than a reason to request a weight-loss prescription for headaches. Before comparing numbers, identify the diagnosis, the existing treatment and the outcome measured. A study of an add-on treatment is not a study of replacing a person’s preventive migraine care.^[1]

What happened in the 31-person study

The investigators enrolled 31 adults with obesity and high-frequency or chronic migraine that had not responded to at least two preventive treatments. After 12 weeks, average monthly headache days declined from 19.8 to 10.7. Liraglutide was added to care, and the study reported little average BMI change. Those figures describe this small selected group; they are not a forecast for an individual, a semaglutide result or proof of a class effect. The treatment schedule was part of the experiment, not a dosing recommendation readers should reproduce through an online service.^[1]

A before-and-after result leaves several explanations open

People often enter a study when symptoms are particularly burdensome. Some improvement can follow even without the tested intervention, and attention, expectations or other changes can influence reported symptoms. A concurrent randomized comparison helps separate those effects. Without it, a statistically significant before-and-after change does not tell us how much improvement liraglutide caused. I would also ask how headache days were recorded, how missing observations were handled and whether other care stayed stable. These are ordinary study-design questions, not reasons to dismiss participants’ experiences or deny that a real treatment effect might exist. Our guide to reading GLP-1 research explains why the comparison group matters as much as the size of a headline change.

Brain-pressure evidence concerns a different condition

A separate randomized trial studied exenatide in 16 women with active idiopathic intracranial hypertension, including raised intracranial pressure and papilledema. Its main outcomes concerned measured pressure, not treatment of ordinary migraine. The trial was small and used a prespecified statistical threshold of 0.1. It offers biological and clinical research context, but does not turn the migraine pilot into a controlled study. Similar symptoms or an interesting mechanism cannot make the populations interchangeable. A clinician needs to establish the cause of a headache before a proposed mechanism is relevant to care.^[2]

The weight-independent claim needs particular care

The migraine investigators did not find a significant relationship between BMI change and headache improvement within their small sample. That observation cannot establish the entire mechanism or prove that weight plays no role. A study can lack the size, duration or range of weight change needed to examine mediation convincingly. I would distinguish the authors’ hypothesis from the measured outcome: headache days changed, while the explanation remains uncertain. Claims about inflammation, brain pressure or a direct neurological effect need their own evidence. They should not be added to a provider’s advertised benefits as though this experiment verified them.

Keep diagnosis and established migraine care in view

NIH describes migraine as a neurological condition with varied symptoms and treatments for attacks and prevention. A new, unusual or changing headache should be discussed clinically rather than automatically attributed to migraine or a GLP-1. Sudden severe headache, new weakness, speech difficulty or other alarming neurological symptoms warrant urgent medical assessment. Do not use a pilot-study article to delay that assessment. If you already have migraine care, bring the research to the clinician managing it and ask how it fits your diagnosis, other medicines and previous treatment responses.^[3]

Use a diary to improve the conversation, not prove the cause

NICE recommends headache diaries to support diagnosis and management. If your clinician suggests one, agree on useful details such as headache frequency, associated symptoms, medicines taken and effects on daily activity. A diary can show a pattern and help evaluate care; it cannot by itself identify which intervention caused a change. If symptoms begin after starting a metabolic medicine, record that timing and contact the prescribing team. Improvement and adverse effects both deserve attention. Avoid editing out inconvenient days or changing multiple treatments simply to test a theory you found online. Bring questions about your existing preventive and rescue medicines as well as the new research. A change in one headache measure should not erase the importance of functioning, tolerability or the ability to follow the treatment plan.^[4]

Do not shop for a migraine result through a weight-loss service

A platform’s GLP-1 offering does not establish that it treats migraine or can coordinate neurological care. If there is an independent clinical reason to consider obesity or diabetes treatment, ask how your existing migraine medicines and symptoms will be reviewed. Compare the service only after that scope is clear. My reading of this research is hopeful but limited: it identifies a potentially useful question and a need for controlled confirmation. It does not identify a preferred telehealth company, justify a compounded substitute or offer an evidence-based migraine dosing plan. For headaches arising during treatment, see our semaglutide headache guide. For a service comparison, our Sesame Care review describes an appointment model; confirm the individual clinician’s expertise separately.

Continue your research

• GLP-1s after bariatric surgery: recurrence and a suboptimal response are different
• GLP-1s and Parkinson’s: mixed trial results and an important 2026 notice
• GLP-1s before hip replacement: lower complication rates are not a timing rule